Metronidazol

Evidensnivå: L5

Förutsagda indikationer: 0 st

---

Innehållsförteckning

1. Metronidazol
2. Metronidazole: Drug Repurposing Pre-Screening Report
   1. One-Sentence Summary
   2. Quick Overview
   3. Why No Prediction Could Be Generated
   4. Conclusion and Next Steps
   5. Ansvarsfriskrivning

---

## Apotekarens bedömningsrapport

Metronidazole: Drug Repurposing Pre-Screening Report

One-Sentence Summary

Metronidazole (INN: METRONIDAZOL) is a well-established antimicrobial agent widely used for anaerobic bacterial and protozoal infections. This Evidence Pack contains no TxGNN-predicted indications, no clinical trial evidence, and no literature evidence — the pipeline did not return a repurposing candidate for evaluation. The current data state is insufficient to produce a full repurposing assessment; a Hold decision is recommended until the data gaps are resolved.

---

Quick Overview

Item	Content
Original Indication	No approved indication recorded in Sweden
Predicted New Indication	Not available — predicted_indications list is empty
TxGNN Prediction Score	N/A
Evidence Level	Not assessable
Sweden Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

---

Why No Prediction Could Be Generated

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological knowledge, Metronidazole belongs to the nitroimidazole class; its activity against anaerobes and protozoa has been extensively proven clinically. However, because the TxGNN model returned an empty predicted_indications array, there is no model-generated repurposing candidate to evaluate, and no mechanistic bridge to a new indication can be assessed at this stage.

The most probable cause is a drug identity resolution failure: the query used the spelling METRONIDAZOL (INN without the final "e"), which may not have matched the node label used in the TxGNN knowledge graph. The DrugBank query did return one result (query_log id 3), but the resolved data was not populated into the drug fields, suggesting a downstream mapping error.

---

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack returned zero predicted indications and zero approved authorizations in Sweden, leaving no repurposing candidate to assess. The pipeline cannot be evaluated until the data gaps below are resolved.

To proceed, the following is needed:

• Re-run TxGNN query using the correct node identifier — try Metronidazole (with final "e"), DrugBank ID DB00916, and MeSH concept D008795 to ensure graph node matching
• Populate MOA data from DrugBank — the DrugBank query succeeded (result_count: 1) but the data was not written into drug.original_moa; extract pharmacodynamics, mechanism, and categories from that record
• Retrieve package insert warnings — TFDA/MPA package insert query succeeded (result_count: 1) but safety.key_warnings and safety.contraindications remain empty; parse the PDF to fill these fields
• Confirm Sweden registration status — Metronidazole products (e.g., Flagyl) are marketed in many European countries; verify whether any MPA (Swedish Medical Products Agency) authorizations exist under alternative spellings or brand names
• Re-run DDI query using the resolved DrugBank ID to capture known interactions (warfarin, lithium, alcohol, disulfiram, etc.)

  Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning. Klinisk validering krävs före klinisk tillämpning.

---